机构：[1]Peoples Hosp Nan Hai, Foshan, Peoples R China[2]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China广东省中医院[3]Guangdong Prov Tradit Chinese Med Hosp, Guangzhou, Peoples R China广东省中医院[4]OrigiMed, Shanghai, Peoples R China[5]Zhejiang Univ Int Hosp, Hangzhou, Zhejiang, Peoples R China
第一作者机构：[1]Peoples Hosp Nan Hai, Foshan, Peoples R China[2]Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China[3]Guangdong Prov Tradit Chinese Med Hosp, Guangzhou, Peoples R China[4]OrigiMed, Shanghai, Peoples R China[5]Zhejiang Univ Int Hosp, Hangzhou, Zhejiang, Peoples R China
推荐引用方式(GB/T 7714)：
Gu Weiguang,Li Yong,Hong Hongxi,et al.Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients.[J].JOURNAL OF CLINICAL ONCOLOGY.2018,36(15):doi:10.1200/JCO.2018.36.15_suppl.e24061.
APA：
Gu, Weiguang,Li, Yong,Hong, Hongxi,Liu, Bai,Wang, Aodi...&Wang, Kai.(2018).Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients..JOURNAL OF CLINICAL ONCOLOGY,36,(15)
MLA：
Gu, Weiguang,et al."Circulating tumor DNA analysis for osimertinib resistance Chinese NSCLC patients.".JOURNAL OF CLINICAL ONCOLOGY 36..15(2018)
医学